Renal and cardiovascular safety of DPP-4 inhibitors with sulfonylureas in the treatment of patients with type 2 diabetes mellitus with advanced chronic kidney disease

Chronic kidney disease (CKD) is a common comorbid disease in people with type 2 diabetes (T2D) in all countries (25-40%), placing a huge health and economic burden on

Chronic kidney disease is staged

In conventional GLA regimens, metformin is contraindicated in patients with eGFR less than 30 ml / min / 1.

In the novel GLA treatment regimen, sodium-glucose cotransporter 2 inhibitors are not approved for use in patients with

To date, no studies have evaluated the association

The researchers made use of the National Health Insurance Research Database

A total of 1204 pairs of DPP4i and SU users were analyzed

Preliminary analysis of the event rate (/100 person-years) and risk ratio (95% CI) of the findings of the study under intention therapy

Overall, in patients with T2D and advanced CKD, the use of DPP4is has a comparable safety profile with SUs in terms of renal and cardiovascular outcomes and reduces the risk

References: Yang CT, Lin WH, Li LJ, Ou HT, Kuo S.